Business Context and Reporting Period
Company: TECHNE Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 1995
Overview: TECHNE is a holding company with two wholly-owned subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in Minneapolis, MN, and R&D Systems Europe Ltd. (R&D Europe) in Abingdon, England. The company operates in two primary segments: Hematology (controls and calibrators for blood analysis instruments) and Biotechnology (cytokines, antibodies, and assay kits for research and clinical diagnostics). The company is a dominant supplier of cytokine-related products in the research marketplace and the third-largest supplier of hematology controls.
Key Financial Metrics
| Metric | Fiscal 1995 | Fiscal 1994 | Fiscal 1993 |
|---|---|---|---|
| Net Sales | $47,716,166 | $40,329,632 | $28,737,821 |
| Gross Margin | $29,252,569 (61.3%) | $23,341,009 (57.9%) | $15,598,216 (54.3%) |
| Net Earnings | $6,706,042 | $5,093,662 | $4,382,275 |
| Earnings Per Share | $0.70 | $0.54 | $0.46 |
| Research & Development Expenses | $8,604,398 | $6,470,751 | $3,663,619 |
| Cash & Cash Equivalents | $5,317,493 | $5,878,346 | $3,979,114 |
| Short-term Investments | $10,627,730 | $4,987,701 | N/A |
| Total Assets | $34,062,275 | $26,805,521 | $20,374,000 |
| Long-term Debt | $0 | $0 | $30,000 |
| Stockholders' Equity | $29,520,095 | $22,954,706 | $17,758,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 18% to $47.7 million, driven primarily by a 33% increase in R&D Europe sales and a 13% increase in R&D Systems sales. Approximately 59% of the consolidated sales increase was attributed to R&D Systems' Quantikine immunoassay kits.
- Margin Expansion: Gross margin percentage improved from 57.9% to 61.3%. This was largely due to favorable exchange rate variances benefiting R&D Europe and increased higher-margin retail sales in the Hematology Division.
- Profitability: Net earnings rose 32% to $6.7 million. Earnings before taxes increased to $9.6 million, driven by higher sales and margins in the Biotechnology and European divisions, partially offset by a slight decrease in Hematology Division earnings.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 21% due to added staff and marketing costs. R&D expenses increased 33% to $8.6 million, reflecting new product development and payments under a Joint Biological Research Agreement with British Bio-technology Group plc.
- Liquidity: Cash and short-term investments totaled $15.9 million, a 47% increase from the prior year. The company has no long-term debt and an unsecured line of credit of $750,000.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Future Growth: Management anticipates sales increases in fiscal 1996 from both U.S. and European subsidiaries due to increased volumes of current products and the release of new products.
- Capital Expenditures: Planned capital additions for fiscal 1996 are approximately $6.2 million, including a $4.5 million expansion of the Biotechnology Division's research and manufacturing facilities (90,000 sq. ft.).
- Share Repurchases: The company repurchased 45,000 shares in fiscal 1995 and plans to purchase an additional $4.4 million of common stock in fiscal 1996, subject to market conditions.
- Dividends: The company has never paid cash dividends and plans to retain earnings for business operations.
Risks and Contingencies
- Technological Obsolescence: The biotechnology industry faces rapid technological change; competitors with greater resources may develop superior products.
- Patents and IP: The company relies on licenses from third parties (e.g., Genentech, Stanford University, Merck) for key technologies. There is a risk of unintentional infringement or failure to obtain necessary patents.
- Regulatory Approval: While research products do not require FDA clearance, clinical diagnostic products do. Delays or failures in obtaining FDA approval for new clinical kits could adversely affect revenue.
- Key Personnel: Success depends on attracting and retaining qualified scientific and production personnel.
- Raw Materials: Primary raw materials include whole blood. While costs have risen due to HIV/hepatitis testing requirements, the company does not anticipate a serious adverse effect.
Investor Verification Checklist
- Revenue Concentration: Verify that no single customer accounts for more than 10% of revenues (confirmed for 1994 and 1995).
- Patent Licenses: Review the terms and royalty rates of licenses held from Genentech, Stanford, and Merck, which cover a significant portion of sales ($7.5 million in 1995).
- Capital Expenditure Funding: Confirm the company's ability to fund the planned $6.2 million in capital additions for fiscal 1996 using existing cash and investments.
- Foreign Operations: Assess the impact of exchange rate fluctuations on R&D Europe's margins, which contributed significantly to the 1995 margin expansion.
- R&D Pipeline: Monitor the progress of new cytokine assay kits and hematology controls currently in development, as future growth depends on successful commercialization.